RxDoctor Payments Data

Nadeem Rahman, MD

Urology · Clovis, CANPI 1467426478

Payments from drug & device makers

$42,619in general payments, 2019–2025

Across 534 payments — averaging $79.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$31K
  • Angiodynamics, Inc.$2K
  • Astellas Pharma US Inc$2K
  • Sumitomo Pharma America, Inc.$790
  • Johnson & Johnson$705
  • Boston Scientific$684
  • plus $5K from 45 others

What the payments were for

  • Speaking & faculty fees$29,00068%
  • Travel & lodging$1,1353%
  • Food & beverage$11,78528%
  • Education$6331%
  • Gifts$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,619 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$768,167
Medicare patients
1,387
Services billed
172,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide43$592,875
MyrbetriqMirabegron88$105,159
GemtesaVibegron113$89,680
OrgovyxRelugolix14$37,762
XyostedTestosterone Enanthate22$23,682
Tamsulosin Hcl595$11,657
Finasteride335$4,764
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst184$3,475
Dutasteride51$1,624
Silodosin16$1,524
Estradiol21$1,492
Oxybutynin Chloride ErOxybutynin Chloride33$1,426
Tadalafil14$1,229
Oxybutynin Chloride42$1,137
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen131$1,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$705$592,87543 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$790$127,443127 claims
Astellas Pharma US IncMyrbetriq$1,641$105,15988 claims
Antares Pharma, Inc.Xyosted$31,402$23,68222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in Clovis

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →